Nachrichten zur Gilead Sciences Inc. Aktie

Gilead Sciences, Inc. (GILD) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

…

5 Powerhouse Stocks to Fuel Your 2024 Portfolio

Stocks Analysis by Investing.com (Ismael De La Cruz) covering: Gilead Sciences Inc, Amazon.com Inc, Pfizer Inc, Berkshire Hathaway B. Read…

Gilead Sciences zahlt vierteljährliche Dividende an die Aktionäre

Der Biotechnologiekonzern Gilead Sciences Inc. (ISIN: US3755581036, NASDAQ: GILD) wird an diesem Donnerstag eine Quartalsdividende in Höhe von 0,75 US-Dollar…

Gilead Sciences zahlt vierteljährliche Dividende an die Aktionäre

Der Biotechnologiekonzern Gilead Sciences Inc. (ISIN: US3755581036, NASDAQ: GILD) wird an diesem Donnerstag eine Quartalsdividende in Höhe von 0,75 US-Dollar…

Hookipa Pharma: +100% mit Ansage - wo lauern die nächsten Deals?

Die österreichische Biotech-Hoffnung Hookipa Pharma (WKN: A2PGMT) gab gestern den Erwerb von Unternehmensanteilen durch seinen Entwicklungspartner Gilead Sciences bekannt. Die…

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

NEW YORK and VIENNA, Austria, Dec. 21, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a…

Gilead Sciences and Compugen strike commercialization deal for immunotherapy program

Gilead Sciences, Inc. (NASDAQ:GILD) announced that it has entered into an agreement with Compugen Ltd (NASDAQ:CGEN) to exclusively license Compugens...…

Compugen signs cancer drug licensing deal with Gilead Sciences

US biopharmaceutical giant Gilead Sciences Inc. (Nasdaq: GILD) today announced an agreement with Israeli clinical-stage cancer immunotherapy company Compugen…

Global Myasthenia Gravis Treatment Market Forecast and Trends 2023-2028, Featuring Profiles of AbbVie, Bausch Health, Gilead Sciences, Merck, Servier and Teva

Dublin, Dec. 18, 2023 (GLOBE NEWSWIRE) -- The "Global Myasthenia Gravis Treatment Market: Forecast and Trends" report has…

Gilead Sciences: Kursziel reduziert

New York (www.aktiencheck.de) - Rating-Update: Terence Flynn, Analyst von Morgan Stanley, belässt die Aktie von Gilead Sciences Inc. (ISIN: US3755581036, WKN:…

Gilead Sciences Is Building A Diversified Portfolio

…

Gilead Sciences, Inc. (GILD) Presents at Piper Sandler 35th Annual Healthcare Conference (Transcript)

…

Gilead Sciences, Inc. (GILD) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)

…

Oncology Drug Discovery & Development Market Expected to Grow at a CAGR of 18.2% from 2023 to 2031 | Reveals InsightAce Study

Companies covered in this study are Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead…

Stocks Stall as Systematic Flows Abate, US Dollar Rebounds: What Comes Next?

Stocks Analysis by Michael Kramer covering: S&P 500, Gilead Sciences Inc, NVIDIA Corporation, US Dollar Index Futures. Read Michael Kramers…

Gilead Sciences: Neues Kursziel

Toronto (www.aktiencheck.de) - Rating-Update: Die Analysten von RBC Capital Markets stufen die Aktie des biopharmazeutischen Unternehmens Gilead Sciences Inc. (ISIN: US3755581036,…

4%-Yielding Gilead Sciences Potential Path To A $100 Stock Price

…

Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)

…

: Arcellx’s stock set to surge after Gilead makes $200 million investment at a 30% premium

Shares of Arcellx Inc. ACLX were set to surge Wednesday, after biotechnology company announced a $200 million equity investment by…

5 Stocks That Raise Dividends Year In, Year Out

Stocks Analysis by Investing.com (Ismael De La Cruz) covering: Gilead Sciences Inc, Marathon Petroleum Corp, Phillips 66, Innovative Industrial Properties…

Gilead Sciences: Slow Progress, But Progress Altogether

…

Gilead Sciences: Ersteinschätzung

Frankfurt (www.aktiencheck.de) - Rating-Update: Die Deutsche Bank stuft die Aktie von Gilead Sciences Inc. (ISIN: US3755581036, WKN: 885823, Ticker-Symbol: GIS, NASDAQ-Symbol:…

Gilead Sciences: Kursziel angehoben

London (www.aktiencheck.de) - Rating-Update: Die Analysten von Barclays stufen die Aktie von Gilead Sciences Inc. (ISIN: US3755581036, WKN 885823, Ticker-Symbol: GIS,…

Tech and biotech firms slash hundreds of Bay Area jobs as layoffs widen

Splunk, Juniper Networks, Zymergen and Gilead Sciences have disclosed decisions to slash hundreds of jobs in the Bay Area.…

Gilead Sciences slips despite Q3 beat and guidance raise

…

Gilead Sciences declares $0.75 dividend

…

Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript

GILD earnings call for the period ending September 30, 2023.…

Gilead Sciences, Inc. (GILD) Q3 2023 Earnings Call Transcript

…

Gilead Sciences 3Q results top estimates on cancer and HIV drug sales

Gilead Sciences Inc after Tuesday’s close announced third quarter 2023 adjusted earnings per share (EPS) of $2.29, surpassing the analyst…

Gilead Sciences, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

: Gilead stock rises on top-, bottom-line beats

Gilead Sciences Inc.’s GILD stock climbed 2% in extended trading Tuesday after the pharmaceutical company reported quarterly results that topped…

ROUNDUP: EU sichert sich bis zu 2,25 Millionen Flaschen Remdesivir gegen Covid

BRÜSSEL (dpa-AFX) - Die Europäische Union hat sich weitere bis zu 2,25 Millionen Fläschchen des Corona-Medikaments…

EU sichert sich bis zu 2,25 Millionen Flaschen Remdesivir gegen Covid

BRÜSSEL (dpa-AFX) - Die Europäische Union hat sich weitere bis zu 2,25 Millionen Fläschchen des Corona-Medikaments…

dpa-AFX ProFeed